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OBJECTIVES The purpose of this study was to compare the efficacy of medical treatment with percutaneous
closure of patent foramen ovale (PFO).
BACKGROUND Patients with cryptogenic stroke and PFO are at risk for recurrent cerebrovascular events.
METHODS We compared the risk of recurrence in 308 patients with cryptogenic stroke and PFO, who
were treated either medically (158 patients) or underwent percutaneous PFO closure (150
patients) between 1994 and 2000.
RESULTS Patients undergoing percutaneous PFO closure had a larger right-to-left shunt (p  0.001;
95% confidence interval [CI] 1.38 to 3.07) and were more likely to have suffered more than
one cerebrovascular event (p  0.03; 95% CI 1.04 to 2.71). At four years of follow-up,
percutaneous PFO closure resulted in a non-significant trend toward risk reduction of death,
stroke, or transient ischemic attack (TIA) combined (8.5% vs. 24.3%; p  0.05; 95% CI 0.23
to 1.01), and of recurrent stroke or TIA (7.8% vs. 22.2%; p  0.08; 95% CI 0.23 to 1.11)
compared with medical treatment. Patients with more than one cerebrovascular event at
baseline and those with complete occlusion of PFO were at lower risk for recurrent stroke or
TIA after percutaneous PFO closure compared with medically treated patients (7.3% vs.
33.2%; p  0.01; 95% CI 0.08 to 0.81, and 6.5% vs. 22.2%; p  0.04; 95% CI 0.14 to 0.99,
respectively).
CONCLUSIONS Percutaneous PFO closure appears at least as effective as medical treatment for prevention of
recurrent cerebrovascular events in cryptogenic stroke patients with PFO. It might be more
effective than medical treatment in patients with complete closure and more than one
cerebrovascular event. (J Am Coll Cardiol 2004;44:750–8) © 2004 by the American
College of Cardiology Foundationu
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ihe etiology of ischemic stroke remains unknown in up to
0% of patients despite an extensive diagnostic evaluation,
nd it is referred to as cryptogenic (1). The association of
atent foramen ovale (PFO) with cryptogenic stroke ini-
ially observed by Lechat et al. (2) and Webster et al. (3) has
een confirmed in a recent meta-analysis of case-control
tudies (4) and in the prospective Patent foramen ovale In
See page 759
ryptogenic Stroke Study (PICSS) (5). Patients with cryp-
ogenic stroke related to PFO are at risk for recurrence
espite medical treatment (5–8), a risk that is particularly
ronounced in patients with PFO and associated atrial
eptal aneurysm (7,9,10). Paradoxical embolism via a PFO
as been implied to be the most likely stroke mechanism
11), and therefore therapeutic measures for secondary
revention are intended to eliminate thrombus formation,
aradoxical embolization, or both.
From the Departments of *Cardiology and †Neurology, University Hospital,
ern, Switzerland.
Manuscript received September 7, 2003; revised manuscript received May 9, 2004,rccepted May 11, 2004.Percutaneous PFO closure is a catheter-based technique
sing atrial septal occlusion devices. It was initially advo-
ated for prevention of recurrent stroke in 1992 (12), and
afety and feasibility have been addressed in several studies
12–19). However, the therapeutic efficacy of percutaneous
FO closure as an adjunct or alternative to medical treat-
ent in cryptogenic stroke patients with PFO is unknown.
his non-randomized study compares the risk of recurrent
erebrovascular events in patients with cryptogenic stroke
nd PFO who underwent percutaneous PFO closure or
eceived medical treatment alone.
ETHODS
atients. We identified all patients with transient ischemic
ttack (TIA) or ischemic stroke, who were admitted to our
niversity hospital stroke center between January 1994 and
ugust 2000. The diagnosis of ischemic stroke was based on
he symptoms and signs of a suddenly occurring neurologic
eficit, and the corresponding findings on computed to-
ography or magnetic resonance imaging scans. Transient
schemic attack was defined as a focal neurologic deficit
esolving completely within 24 h. Doppler and color Duplex
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August 18, 2004:750–8 Stroke and Patent Foramen Ovalexamination of the extracranial carotid, the vertebral and
asal intracranial arteries, electrocardiography, and contrast
ransesophageal echocardiography were performed in all
atients. The cerebrovascular event was considered the
esult of paradoxical embolism if the following conditions
ere met: 1) presence of PFO with or without atrial septal
neurysm with spontaneous or provocable right-to-left
hunt as assessed by transesophageal echocardiography; 2)
linically and radiologically confirmed ischemic stroke or
IA; and 3) exclusion of any other identifiable cardiac,
ortic, or cerebrovascular cause. After excluding patients
ithout a PFO or with a concurrent etiology for the
erebrovascular event, 308 patients were classified as having
uffered a cryptogenic stroke presumably related to PFO.
ercutaneous PFO closure was performed in 150 patients,
hereas 158 patients were treated medically. The individual
reatment decision was based on patient and physician
reference.
ransesophageal echocardiography and diagnosis of par-
doxical embolism. The diagnosis of PFO and atrial septal
neurysm was based on contrast transesophageal echocardi-
graphy with an aerated colloid solution injected into an
ntecubital vein at the end of a Valsalva maneuver in all
atients. Patent foramen ovale was defined as flap-like
pening in the atrial septum secundum, with the septum
rimum serving as a one-way valve allowing for permanent
r transient right-to-left shunt. Atrial septal aneurysm was
iagnosed as abnormally redundant interatrial septum with
n excursion of 10 mm into the right or left atrium and a
ase span of at least 15 mm (20). Spontaneous or provoked
ight-to-left shunt was semiquantitatively graded according
o the amount of bubbles detected in the left atrium after
rossing the interatrial septum on a still frame: grade 0 
one, grade 1  minimal (1 to 5 bubbles), grade 2 
oderate (6 to 20 bubbles), and grade 3  severe (20
ubbles) (3).
edical treatment. Patients assigned to medical treatment
ere treated with a vitamin K antagonist or antiplatelet
herapy at the discretion of the attending neurologist.
oumadin was adjusted to a target international normalized
atio of 2.0 to 3.0; acetylsalicylic acid was prescribed at a
ean dose of 233 83 mg/day, and clopidogrel at a dose of
5 mg/day.
ercutaneous PFO closure. The procedure was per-
ormed under local anesthesia and fluoroscopic guidance as
Abbreviations and Acronyms
CI  confidence interval
PFO  patent foramen ovale
PICSS  Patent foramen ovale In Cryptogenic Stroke
Study
RR  risk ratio
TIA  transient ischemic attack3escribed previously (15). Six different device types were
tilized according to availability at different time points,
ncluding the Amplatzer PFO Occluder (n  54), PFO
TAR (n  42), Sideris buttoned device (n  27), Angel
ing device (n  10), Amplatzer ASD Occluder (n  9),
nd CardioSEAL (n  8). Patients were treated with
cetylsalicylic acid 100 mg once daily for six months for
ntithrombotic protection until full device endothelializa-
ion. A contrast transesophageal echocardiography was re-
eated six months after percutaneous PFO closure to assess
or a residual shunt after endothelial overgrowth. Medical
reatment was discontinued in 93 of 150 patients after six
onths. Fifty-seven patients continued medical treatment
ith acetylsalicylic acid 100 mg once daily owing to a
esidual shunt (26 patients) or presence of mild coronary
rtery disease as assessed by coronary angiography (31
atients).
ollow-up evaluation. All family physicians and patients
ere subjected to a structured interview addressing recur-
ence of cerebrovascular events, rehospitalizations, and
evice- or medication-related problems. Death, recurrent
schemic stroke, TIA, or peripheral embolism were consid-
red adverse events. Patients with suspected recurrent cere-
rovascular events were reexamined by a neurologist, and an
maging study of the brain was repeated. Follow-up infor-
ation was available for all patients at some point in time,
ut two patients in the medical treatment group and three
atients in the percutaneous PFO closure group were
ubsequently lost to follow-up as a result of address changes.
atients gave informed consent, and the study was approved
y the local ethics committee.
tatistical analysis. Continuous variables are expressed as
ean  1 SD and were compared by a two-sided, unpaired
test. Categorical variables are reported as counts and
ercentages and were compared by chi-square analysis. The
aplan-Meier survival analysis was used to assess the risk of
ecurrent events. The log-rank test was used to compare the
umulative incidence curves between the treatment groups.
redictors of recurrent events according to treatment as-
ignment were analyzed by a Cox proportional hazards
odel. Statistical significance was assumed with a p value
0.05. All data were analyzed with the use of SPSS
oftware (version 10.0, SPSS Inc., Chicago, Illinois).
ESULTS
he two groups were comparable with respect to age,
ender, cardiovascular risk factors, and associated atrial
eptal aneurysm (Tables 1 and 2). Patients who underwent
ercutaneous PFO closure were more likely to have suffered
ore than one cerebrovascular event before inclusion in the
tudy (p  0.03; risk ratio [RR] 1.68; 95% confidence
nterval [CI] 1.04 to 2.71) and had a larger right-to-left
hunt at baseline (p  0.001; RR 2.01; 95% CI 1.38 to
.07).
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Stroke and Patent Foramen Ovale August 18, 2004:750–8edical treatment. Oral anticoagulation with the vitamin
antagonist coumadin was initially used in 79 patients,
hereas 79 patients were treated with antiplatelet therapy
acetylsalicylic acid in 77 patients and clopidogrel in 2
atients). Baseline clinical and echocardiographic character-
stics stratified according to type of medical treatment are
ummarized in Tables 1 and 2. Patients treated with oral
nticoagulants had more frequently suffered an ischemic
troke as the cerebrovascular index event and a higher
revalence of PFO-associated atrial septal aneurysm than
atients treated with antiplatelet drugs. In 26 patients, oral
nticoagulants were substituted with acetylsalicylic acid after
mean of 12  11 months. No major bleeding complica-
ions were observed during follow-up. Nine patients discon-
inued antithrombotic therapy because of malcompliance.
ercutaneous PFO closure. Percutaneous PFO closure
as successful in 148 patients (99%) and failed in 2 patients.
eriprocedural complications were observed in nine patients
6%), and they included embolization of the device in four
atients, air embolism in three patients, and vascular access
ite problems in two patients. There were no procedural
eaths, no requirement for open-heart surgery, and none of
he procedural complications resulted in long-term se-
Table 1. Baseline Clinical Characteristics
Percutaneou
PFO Closur
(n  150)
Age (yrs) 50 12
Male gender 80 (53%)
Follow-up (yrs) 2.1 1.6
Cardiovascular risk factors
Arterial hypertension 42 (28%)
Diabetes mellitus 6 (4%)
Smoking 49 (33%)
Total cholesterol (mmol/dl) 5.5 1.2
Cerebrovascular index event
Transient ischemic attack 53 (35%)
Ischemic stroke 97 (65%)
Number of previous
cerebrovascular events
Mean number of events 1.8  1.1
More than one event 59 (39%)
*p  0.03 versus percutaneous PFO closure. †p  0.001 ver
PFO  patent foramen ovale.
Table 2. Baseline Echocardiographic Characte
Percutaneo
PFO Closu
(n  150
Atrial septal anatomy
PFO only 113 (75%
PFO and atrial septal aneurysm 37 (25%
Interatrial right-to-left shunt
Small 5 (3%)
Moderate 26 (17%
Large 119 (80%
Left atrial size (mm) 36  6
*p  0.001 versus percutaneous PFO closure. †p  0.01 ver
PFO  patent foramen ovale.uelae. Complete PFO closure as assessed by transesopha-
eal echocardiography at six months was achieved in 83% of
atients, whereas a small, moderate, or large shunt persisted
n 10%, 3%, or 4% of patients, respectively.
ecurrent events. Outcome events during a mean follow-
p of 2.3  1.7 years are summarized in Tables 3 through
. Three deaths, 7 ischemic strokes, and 14 TIAs were
bserved in the medical treatment group, compared with 1
eath, 2 ischemic strokes, and 7 TIAs in the percutaneous
FO closure group. In the medical treatment group, one
troke and five TIAs were encountered with oral anticoag-
lation, six strokes and six TIAs with antiplatelet treatment,
nd three TIAs in patients who had discontinued antiplate-
et therapy. No peripheral embolic events were encountered
uring follow-up in either group.
At four years of follow-up, percutaneous PFO closure
howed a non-significant trend toward a lower risk in the
ombined end point of death, stroke, or TIA (8.5% vs.
4.3%; p  0.05; RR 0.48; 95% CI 0.23 to 1.01) (Fig. 1)
hen compared with medical treatment. There was no
ignificant difference in the risk of recurrent stroke or TIA
etween percutaneous PFO closure and medical treatment
7.8% vs. 22.2%; p  0.08; RR 0.51; 95% CI 0.23 to 1.11)
Medical
Treatment
(n  158)
Oral
Anticoagulants
(n  79)
Antiplatelet
Agents
(n  79)
51  13 51  13 51  14
92 (58%) 45 (57%) 47 (59%)
2.4  1.9 2.4  1.8 2.4  2.0
50 (32%) 21 (27%) 29 (37%)
14 (9%) 6 (8%) 8 (10%)
51 (33%) 25 (32%) 26 (33%)
5.8  1.3 5.6  1.4 6.0  1.0
†
40 (25%) 10 (13%) 30 (38%)
118 (75%) 69 (87%) 49 (62%)
*
1.5  1.0 1.5  0.9 1.5  1.0
44 (29%) 24 (30%) 20 (25%)
al anticoagulants.
Medical
Treatment
(n  158)
Oral
Anticoagulants
(n  79)
Antiplatelet
Agents
(n  79)
†
123 (78%) 55 (70%) 68 (86%)
35 (22%) 24 (30%) 11 (14%)
*
17 (11%) 4 (5%) 13 (16%)
44 (28%) 23 (29%) 21 (27%)
97 (61%) 52 (66%) 45 (57%)
36  5 37  5 36  6
al anticoagulants.s
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August 18, 2004:750–8 Stroke and Patent Foramen OvaleFig. 2) in the overall study group. Outcome was not
ifferent comparing treatment with oral anticoagulants and
ntiplatelet drugs (Table 4). Although there were no differ-
nces in outcome between percutaneous PFO closure and
ral anticoagulation, the combined end point of death,
troke, or TIA was significantly lower after percutaneous
FO closure than with antiplatelet therapy (8.5% vs. 28.3%;
 0.03; RR 0.43; 95% CI 0.20 to 0.94) (Table 4).
Univariate predictors of recurrent stroke or TIA accord-
ng to treatment assignment are summarized in Figure 3.
atients with complete PFO occlusion after percutaneous
FO closure had a significantly lower risk of recurrent
troke or TIA than medically treated patients (6.5% vs.
2.2%; p  0.04; RR 0.37; 95% CI 0.14 to 0.99) (Fig. 4).
imilarly, patients with more than one cerebrovascular event
t baseline, had a significantly lower risk of recurrent stroke
r TIA after percutaneous PFO closure than medically
reated patients (7.3% vs. 33.2%; p  0.01; RR 0.26; 95%
I 0.08 to 0.81) (Fig. 5). There were no significant
ifferences in the risk of recurrent events between treatment
able 3. Recurrent Events
Events
PFO
Closure
Medica
Treatmen
ntire patient cohort 150 158
Recurrent death, stroke, or TIA 10 24
Death 1 3
Recurrent stroke or TIA 9 21
Recurrent stroke 2 7
Recurrent TIA 7 14
atients with complete PFO occlusion after
percutaneous PFO closure
122 158
Recurrent stroke or TIA 5 21
atients with more than one cerebrovascular
event at baseline
59 44
Recurrent stroke or TIA 4 11
Probabilities of events were derived from Kaplan-Meier analyses. †Hazard ratios a
alculated with the log-rank test.
CI  confidence interval; PFO  patent foramen ovale; TIA  transient ischem
able 4. Recurrent Events Stratified According to Treatment
PFO
Closure
Oral
Anticoagulants A
ecurrent death, stroke, or TIA 8.5% 13.3%
eath 0.7% 0%
ecurrent stroke or TIA 7.8% 19.3%
ecurrent stroke 2.1% 1.8%
ecurrent TIA 5.9% 17.8%
atients with more than one
cerebrovascular event at
baseline
Recurrent stroke or TIA 6.5% 17.9%
Probabilities of events were derived from Kaplan-Meier analyses; p values were calc
Asp  acetylsalicylic acid; OAC  oral anticoagulation; PFO  patent foramen ovale;roups with respect to gender, older age, previous stroke,
rterial hypertension, smoking, hypercholesterolemia, dia-
etes, or associated atrial septal aneurysm.
ISCUSSION
here is considerable evidence that PFO is not only
ssociated but the cause of ischemic stroke in cryptogenic
troke patients. First, PFO-mediated paradoxical embolism
s pathophysiologically plausible, and thrombus trapped
ithin the PFO has been documented iteratively (21–23).
econd, larger PFO size has been associated with a higher
ecurrence rate, suggesting a dose-response relationship
24–28). Third, the higher frequency of deep venous
hrombosis in stroke patients with PFO supports the
oncept of thrombi crossing the PFO to cause paradoxical
mbolism (29–32). Fourth, the Stroke Prevention Assess-
ent of Risk in a Community study (9) suggested paradox-
cal embolism as the principal mechanism of stroke in
atients with PFO and associated atrial septal aneurysm,
Probability of Event at 4 Years*
Hazard Ratio
(95% CI)†
p
Value‡
PFO
Closure
Medical
Treatment
8.5% 24.3% 0.48 (0.23–1.01) 0.05
0.7% 2.7% 0.33 (0.03–3.22) 0.32
7.8% 22.2% 0.51 (0.23–1.11) 0.08
2.1% 7.6% 0.36 (0.08–1.74) 0.19
5.9% 15.8% 0.58 (0.23–1.44) 0.23
6.5% 22.2% 0.37 (0.14–0.99) 0.04
7.3% 33.2% 0.26 (0.08–0.81) 0.01
% confidence intervals were derived from Cox regression analyses. ‡p values were
ck.
robability of Event at 4 Years*
latelet
p Value
OAC vs. Asp
p Value
Closure vs. OAC
p Value
Closure vs. ASP
3% 0.47 0.32 0.03
9% 0.24 0.58 0.16
4% 0.74 0.25 0.07
2% 0.30 0.82 0.11
9% 0.74 0.24 0.29
6% 0.33 0.18 0.005
with the log-rank test.l
t
nd 95
ic attaP
ntip
28.
3.
25.
10.
16.
42.
ulated
TIA  transient ischemic attack.
Table 5. Individual Recurrent Events Grouped by Treatment Allocation
Age Gender ASA
RF
(n)
Previous
TIA (n)
Previous
Strokes
(n)
Time of
Event Type of Event
Antithrombotic
Treatment at
Time of Event
Shunt
Grade*
Medical treatment group
1 39 F yes 4 1 0 48 months TIA Oral anticoagulants 2
2 56 M no 3 0 1 73 months TIA Oral anticoagulants 3
3 67 M no 2 1 0 42 months Minor cryptogenic stroke Acetylsalicylic acid 3
4 54 M no 0 4 1 9 months TIA Oral anticoagulants 3
5 42 M no 4 0 1 3 months Minor cryptogenic stroke Acetylsalicylic acid 3
6 35 F no 0 2 0 3 months TIA Oral anticoagulants 3
7 42 M no 1 1 1 4 months Fatal road traffic accident Acetylsalicylic acid 3
8 55 F no 2 0 1 17 months Minor cryptogenic stroke Acetylsalicylic acid 3
9 55 F no 1 1 1 7 months TIA Acetylsalicylic acid 3
10 62 M yes 3 0 1 48 months TIA Acetylsalicylic acid 3
11 15 F no 0 0 1 33 months TIA Acetylsalicylic acid 1
12 68 F yes 3 0 1 34 months TIA Oral anticoagulants 2
13 55 M no 1 1 0 36 months TIA Discontinued 3
14 77 M yes 1 0 1 33 months TIA Acetylsalicylic acid 2
15 31 M no 1 3 0 32 months TIA Acetylsalicylic acid 1
16 64 M no 4 0 1 22 months Sudden cardiac death, known CAD Acetylsalicylic acid 2
17 74 M yes 1 0 2 28 months Major cryptogenic stroke Acetylsalicylic acid 3
18 77 M no 0 4 0 12 months TIA Acetylsalicylic acid 2
19 52 M no 3 4 0 26 months Minor cryptogenic stroke Acetylsalicylic acid 2
20 33 M no 1 1 1 17 months Minor cryptogenic stroke Acetylsalicylic acid 3
21 53 F no 0 0 1 7 months Fatal lung cancer Discontinued 3
22 74 F no 1 4 0 3 months TIA Discontinued 2
23 41 M no 0 1 1 13 months TIA Discontinued 1
24 37 F no 1 0 2 1 month Minor cryptogenic stroke Oral anticoagulants 3
Residual
Shunt
Grade
PFO closure group
1 41 M no 2 0 1 8 months TIA Acetylsalicylic acid
(residual shunt)
1
2 47 F no 1 2 6 3 weeks TIA Acetylsalicylic acid
(per protocol)
2
3 74 M yes 2 0 1 22 months TIA (large vessel; hypesthesia right arm;
new large plaque at carotid
bifurcation)
Acetylsalicylic acid
(associated
CAD)
None
4 61 F no 0 1 0 12 months TIA (microangiopathic; internuclear
ophthalmoplegia)
None None
5 74 M no 2 1 2 6 months TIA Acetylsalicylic acid
(per protocol
and associated
CAD)
None
Continued on next page
754
W
indecker
etal.
JACC
Vol.44,No.4,2004
Stroke
and
PatentForam
en
Ovale
August18,2004:750–8
w
r
r
P
a
(
l
p
i
m
l
P
t
b
c
c
w
p
ab
le
5
C
on
ti
nu
ed
A
ge
G
en
de
r
A
SA
R
F
(n
)
P
re
vi
ou
s
T
IA
(n
)
P
re
vi
ou
s
St
ro
ke
s
(n
)
T
im
e
of
E
ve
nt
T
yp
e
of
E
ve
nt
A
nt
it
hr
om
bo
ti
c
T
re
at
m
en
t
at
T
im
e
of
E
ve
nt
Sh
un
t
G
ra
de
*
6
59
M
no
2
1
1
6
m
on
th
s
T
IA
A
ce
ty
ls
al
ic
yl
ic
ac
id
(r
es
id
ua
ls
hu
nt
)
1
7
24
M
no
0
0
1
20
m
on
th
s
M
in
or
cr
yp
to
ge
ni
c
st
ro
ke
N
on
e
N
on
e
8
39
F
no
3
0
1
3
da
ys
M
in
or
cr
yp
to
ge
ni
c
st
ro
ke
A
ce
ty
ls
al
ic
yl
ic
ac
id
(p
er
pr
ot
oc
ol
)
1
9
64
M
no
1
0
1
4
m
on
th
s
Fa
ta
lr
oa
d
tr
af
fic
ac
ci
de
nt
A
ce
ty
ls
al
ic
yl
ic
ac
id
(p
er
pr
ot
oc
ol
)
N
on
e
10
45
F
no
1
2
3
10
m
on
th
s
T
IA
N
on
e
N
on
e
Sh
un
t
gr
ad
e:
1

sm
al
l,
2

m
od
er
at
e,
3

se
ve
re
.
A
SA

at
ri
al
se
pt
al
an
eu
ry
sm
;C
A
D

co
ro
na
ry
ar
te
ry
di
se
as
e;
P
FO

pa
te
nt
fo
ra
m
en
ov
al
e;
R
F

ca
rd
io
va
sc
ul
ar
ri
sk
fa
ct
or
s;
T
IA

tr
an
si
en
t
is
ch
em
ic
at
ta
ck
.
F
a
p
F
s
755JACC Vol. 44, No. 4, 2004 Windecker et al.
August 18, 2004:750–8 Stroke and Patent Foramen Ovalehereas atrial septal aneurysm without PFO (absence of a
ight-to-left shunt) has been shown to portend no particular
isk for recurrent cerebrovascular events (10). Accordingly,
FO closure has been proposed as a logical therapeutic
pproach for secondary prevention of cerebrovascular events
12,33).
Although several observational studies have reported the
ong-term outcome after medical treatment (5–8,10) and
ercutaneous (12–19) or surgical (34–36) PFO closure, this
s the first study to compare percutaneous PFO closure with
edical treatment for prevention of recurrent cerebrovascu-
ar events in patients with cryptogenic stroke and PFO.
ercutaneous PFO closure was as effective as medical
reatment in the overall study group. It was significantly
etter than medical treatment in the prevention of recurrent
erebrovascular events in two subgroups: patients with
omplete PFO occlusion after the intervention and patients
ith more than one cerebrovascular event at baseline.
The superiority of percutaneous PFO closure when com-
ared with medical treatment in patients with complete
igure 1. Probability of death, recurrent stroke, or transient ischemic
ttack stratified for medical treatment (continuous line) and percutaneous
atent foramen ovale (PFO) closure (dashed line).
igure 2. Probability of recurrent stroke or transient ischemic attack
tratified for medical treatment (continuous line) and percutaneous patentT * foramen ovale (PFO) closure (dashed line).
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Stroke and Patent Foramen Ovale August 18, 2004:750–8FO occlusion is in line with our previously reported
nding that complete compared with incomplete PFO
cclusion results in a significantly lower risk of recurrence in
atients undergoing percutaneous PFO closure (15,16).
his observation lends further support to paradoxical em-
olism being the prevalent mechanism for cerebrovascular
vents in this patient group. Furthermore, it highlights that
omplete PFO occlusion is desirable for therapeutic efficacy
n patients undergoing percutaneous PFO closure, a goal
hich can be achieved in 90% of patients with the most
ecent devices (17,18).
The higher efficacy of percutaneous PFO closure com-
ared with medical treatment in patients with more than
ne cerebrovascular event indicates that these patients
epresent a high-risk population. Indeed, these patients
uffered recurrent cerebrovascular events despite medical
reatment, suggesting inadequate protection by medical
reatment alone. The fact that previous events were more
requent in patients who underwent percutaneous PFO closure
nhances the results in favor of the interventional group. So
Figure 3. Risk ratios according to treatment assignment in subgith complete PFO occlusion.
F
s
f
woes the larger PFO size in the interventional group, another
stablished risk factor for recurrence (24–28).
Event rates between medical treatment and percutaneous
FO closure appeared to separate only after two years of
ollow-up. One explanation for this observation is the
ntention to treat analysis of our study. Thus, patients with
ncomplete PFO closure (17%) were included in the overall
ercutaneous PFO closure group. Because the device be-
omes fully protective only after complete endothelialization
as ensued, a residual shunt during the initial months after
evice implantation may predispose to recurrent events
espite antithrombotic therapy. This observation is vali-
ated by the early separation of cerebrovascular event rates
n patients with complete PFO closure compared with the
edical treatment group (Fig. 4). Another explanation for
he more pronounced separation after two years of
ollow-up could be non-compliance with medical treatment
n patients in the medical treatment group.
The benefits of percutaneous PFO closure in our study
ere associated with a certain risk of procedural complica-
ions, albeit without any long-term sequelae, and with the
. PFO  patent foramen ovale; ASA  atrial septal aneurysm.igure 4. Probability of recurrent stroke or transient ischemic attack
tratified for medical treatment (continuous line) and percutaneous patent
oramen ovale (PFO) closure (dashed line) in the subgroup of patientsigure 5. Probability of recurrent stroke or transient ischemic attack
tratified for medical treatment (continuous line) and percutaneous patent
oramen ovale (PFO) closure (dashed line) in the subgroup of patients
ith more than one cerebrovascular event at baseline.
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August 18, 2004:750–8 Stroke and Patent Foramen Ovalencremental cost of the procedure and the device. Ultimate
roof of paradoxical embolism being the principal stroke
echanism in such patients and of the superiority of
ercutaneous PFO closure over medical treatment will have
o await the results of prospective, randomized trials such as
he Percutaneous Closure of Patent Foramen Ovale and
ryptogenic Embolism trial initiated by our group (16).
Mas et al. (10) recently reported on the clinical
utcome of 581 patients (mean age 42 years) with
ryptogenic stroke, who were treated with acetylsalicylic
cid 300 mg/day and followed for up to 4 years. The risk
f recurrent stroke or TIA at four years was 5.6% in
atients with PFO alone, 19.2% in patients with both
FO and atrial septal aneurysm, 0% in patients with
trial septal aneurysm alone, and 6.2% in patients without
trial septal abnormality. The authors concluded that
atients with both PFO and atrial septal aneurysm are at
ubstantial risk for recurrence requiring additional pre-
entive strategies beyond treatment with acetylsalicylic
cid alone, whereas patients with a PFO alone are at low
isk for recurrence comparable to those patients without
trial septal abnormality. It has been hypothesized, how-
ver, that a large PFO rather than the associated atrial
eptal aneurysm was responsible for the high recurrence
ate in this study (37). We did not observe a significant
ifference in recurrence rates with respect to the addi-
ional presence of atrial septal aneurysm between the
edical treatment and percutaneous PFO closure group
n our study. However, this subgroup represented only
ne-fourth of the entire cohort, and a potential difference
n clinical outcome might have become apparent with a
arger patient group and during longer follow-up. Thus,
atients with PFO and associated atrial septal aneurysm
eserve further investigation with respect to the role of
ercutaneous PFO closure in addition to medical treat-
ent. Despite the low recurrence rate in patients with
FO alone as reported by Mas et al. (10), it cannot be
xcluded that percutaneous PFO closure reduces further
vents even in these patients. Notably, patients without
trial septal abnormalities had significantly more compet-
ng stroke risk factors, such as arterial hypertension,
moking, or hypercholesterolemia, than PFO patients,
ossibly camouflaging the PFO risk.
In the prospective PICSS (5), the presence of PFO was
eported not to have an adverse impact on recurrent
erebrovascular events regardless of PFO size and pres-
nce of an atrial septal aneurysm. However, only 42% of
atients included in this study had suffered a cryptogenic
troke as opposed to stroke of known etiology, that is,
arge vessel (11%), lacunar (39%), other determined cause
4%), or conflicting mechanism (4%). Therefore, it comes
s no surprise that PFO was only an innocent bystander
n the majority of patients. Notwithstanding, the inves-
igators were able to reproduce the previously docu-
ented association of PFO with cryptogenic stroke as
ell as a higher prevalence of large PFOs in cryptogenictroke patients than in control subjects of known stroke
ause. The recurrent stroke and death rates at two years
ere 9.5% and 17.9% for cryptogenic stroke patients with
FO receiving warfarin or acetylsalicylic acid, respec-
ively (RR 0.52, 0.16 to 1.67, p  0.3). Although not
ignificant, this corresponds to a 48% event reduction in
avor of warfarin and contrasts with the event rates of
6.5% and 13.2% for warfarin or acetylsalicylic acid
reated patients, respectively, in the entire PICSS cohort
f PFO patients. However, a similar 49% event reduction
n favor of warfarin was observed in cryptogenic stroke
atients without PFO, implying a PFO-independent but
ossibly anticoagulation-responsive stroke mechanism.
The recurrent event rates in our study were similar to
hose in the PICSS patient group (5) but higher than those
eported by Mas et al. (10), suggesting important baseline
ifferences with respect to age, cardiovascular risk factors,
nd number of previous cerebrovascular events. However,
atients in our study were diagnosed and treated according
o identical criteria established by a team of neurologists and
ardiologists at a single institution, thus minimizing case-
o-case variations. Because of the overall low recurrence rate
f stroke, the cost and small risk of device implantation
ust be carefully weighed against the potential therapeutic
enefit.
tudy limitations. The following limitations apply to our
tudy. The most important limitation is the non-
andomized study design, which may confound the re-
ults and introduce bias. However, short of randomized
rials which are not expected to be completed within the
ear future, these data provide important preliminary
esults relevant to this patient population. The diagnosis
f PFO-mediated paradoxical embolism is presumptive,
nd therefore PFO and cryptogenic stroke may coexist
ithout causal relationship in certain patients. Percuta-
eous PFO closure in such patients will not influence
ecurrent cerebrovascular events, a circumstance contrib-
ting to the small recurrence rate despite successful PFO
losure in our and other series. Percutaneous PFO closure
as performed using six different device types employed
uring different time periods. Current devices for percu-
aneous PFO closure achieve complete PFO occlusion in
95% of cases and are associated with complications in
1% of cases (18). This improvement in device perfor-
ance might have a positive impact on clinical outcome
n the future. Discontinuation of antithrombotic treat-
ent in the medical treatment group could be an impor-
ant confounder of the presented data. Thus, it cannot be
xcluded that a considerable portion of patients in the
edical treatment group actually did not take antithrom-
otic treatment at all. However, the limitation of non-
ompliance with medical treatment applies to everyday
linical practice and does not affect the overall finding of
ur study.
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Stroke and Patent Foramen Ovale August 18, 2004:750–8ONCLUSIONS
ercutaneous PFO closure appears at least as effective as
edical treatment for prevention of recurrent cerebrovascu-
ar events in cryptogenic stroke patients related to PFO.
ercutaneous PFO closure may be more effective than
edical treatment in patients with complete PFO closure
nd more than one cerebrovascular event.
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